Calendario›UNCY›Oxylanthanum Carbonate
Oxylanthanum Carbonate
A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis
Ensayo de Unicycive Therapeutics, Inc. en Chronic Kidney Disease Requiring Chronic Dialysis (del registro, en inglés).
- Fase
- Fase 2
- Estado
- Completado
- Participantes
- 106
- Centros
- 7
- Fin del objetivo primario
- may 2024
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, de un solo grupo, abierto. Comenzó en dic 2023.
Qué mide
Incidence of treatment-related AEs leading to study drug discontinuation during the Maintenance Period. (del registro, en inglés) (4 semanas)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe goal of this clinical study is to test the tolerability of oxylanthanum carbonate (OLC) in patients with chronic kidney disease on hemodialysis and have hyperphosphatemia (too much phosphorus in their blood). The main question it aims to answer is whether patients taking OLC for hyperphosphatemia are able to tolerate the drug. Participants will continue with their scheduled dialysis treatments and replace their current phosphate binder drug with OLC.
Ficha completa en ClinicalTrials.gov (NCT06218290), actualizada en jun 2024.